Clinical Trial Search

Primary: Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hrs Post Dosing — -1.04; -1.06; -1.07; -1.15 scores on a scale

Primary: Percentage of Participants With a Vital Pregnancy — 23.9; 26.9 percentage of participants

Primary: Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) — 59.2; 28.3; 23.3; 16.0 percentage of subjects abstinent

Primary: Ongoing Pregnancy Rate at the End of the Study — 27.4; 30.5 percentage of randomized patient — p=0.37

Primary: Ongoing Pregnancy Rate — 40.8; 43.3 percentage of randomized patients — p=0.52

Primary: Changes in Body Fat Mass(kg) — 22.9; 24.3; 22.8; 24.1 kg

Primary: Frequency of ILI(Influenza Like Illness) — 12; 22 participants

Primary: Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables — 24; 6; 2; 1 Participants

Primary: Change in Dizziness Handicap Inventory (DHI) Questionnaire Score — 10.25; 49.6 units on a scale

Primary: Change From Baseline in Brief Pain Inventory (BPI) Questionnaire Item 6 "Pain Right Now" Score at Week 24 (Per Protocol [PP] Population) — -2.8; -3.2 Units on a scale…

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease — 16.9; 19.1; 16.5; 204.6 Titer

Primary: Progression Free Survival (PFS) — 92; 125; 82 Days

Primary: Time to Healing (TTH) of Vesicular Primary Lesion — 7.00; 7.32 Days — p=0.015

Primary: Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population — -1.29; 2.36 SDS

Primary: Change From Baseline in 2-h Postprandial Glucose (Breakfast, Lunch and Dinner) — -56.2; -43.7; -5.5; -43.1 mg / dL